Blog
    Peptide SpotlightFor PhysiciansSeptember 7, 2026

    BPC-157 Evidence Review: Gastric Pentadecapeptide Data

    Evaluate clinical evidence for BPC-157, including its Grade C+ status, phase II ulcerative colitis data, and FDA regulatory safety signals.

    BPC-157 Evidence Review: Gastric Pentadecapeptide Data

    This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

    BPC-157 is a stable gastric pentadecapeptide composed of 15 amino acids. It is a sequence that is both native to and stable within human gastric juice. While it has gained significant attention in preclinical circles for its putative regenerative properties, the clinical landscape is characterized by limited human data and significant regulatory scrutiny.

    1. Clinical Question

    Does the current body of evidence support the clinical efficacy and safety of BPC-157 for soft tissue repair and gastrointestinal indications in humans?

    2. Evidence Snapshot

    • Evidence Grade: C+
    • Study Types: 100+ preclinical studies; Phase II clinical trial for Ulcerative Colitis (UC); Phase I safety trial (cancelled).
    • Regulatory Status: Not FDA approved; FDA Category 2 Bulk Substance (significant safety risk).
    • Key Indications Studied: Ulcerative colitis, acute hamstring muscle strain repair, and healthy volunteer safety.
    • Primary Data Source: Majority of research originates from a single research group at the University of Zagreb.

    3. What the Research Shows

    The research profile for BPC-157 is bifurcated between extensive animal data and sparse human clinical trials. More than 100 preclinical studies have investigated the peptide's effects, primarily focused on tissue healing and cytoprotection.

    In human subjects, a Phase II clinical trial has been completed for the indication of Ulcerative Colitis (UC). Additionally, a Phase II trial (NCT074375) was registered to evaluate BPC-157 for acute hamstring muscle strain repair, though the current status of results for this specific indication remains TBD.

    Safety data is notably limited. A Phase I trial (NCT02637284) intended to evaluate BPC-157 in 42 healthy volunteers was cancelled in 2016, and the results of that enrollment were never submitted. Because the vast majority of existing data is derived from animal models, the translatability of these findings to human clinical outcomes is not yet fully established.

    4. Mechanism

    Based on the provided preclinical data, the mechanism of action for BPC-157 involves several distinct cellular pathways:

    • Angiogenesis and Nitric Oxide: The peptide promotes angiogenesis and modulates the nitric oxide system in a bidirectional manner.
    • Growth Factor Modulation: It upregulates growth factor receptors located on fibroblasts.
    • Intracellular Signaling: It stimulates several pathways, including Egr-1, NAB2, FAK-paxillin, and JAK-2.
    • Barrier Function: The peptide has been shown to enhance tight junction proteins, contributing to the integrity of cellular barriers.

    5. Limitations of the Evidence

    There are significant evidence gaps that clinicians must consider. The primary limitation is that the vast majority of the 100+ studies are animal-only. Furthermore, the research is highly concentrated, originating largely from a single research group at the University of Zagreb, which lacks independent multicenter validation.

    From a regulatory perspective, BPC-157 faces substantial hurdles. In September 2023, the FDA classified BPC-157 as a Category 2 bulk substance, indicating it is ineligible for routine compounding due to significant safety risks. The FDA has raised concerns regarding immunogenicity and a general lack of human safety data.

    Warning letters have also been issued by the FDA, including a 2020 letter to Tailor Made Compounding and a 2020 letter to Predator Nutrition. The lack of regulated sourcing is cited as a major safety concern for this compound.

    6. Clinical Takeaway

    While BPC-157 (Grade C+) demonstrates interesting mechanisms in preclinical models regarding fibroblast modulation and angiogenesis, there is a profound lack of completed, peer-reviewed human clinical trial data. The cancellation of Phase I safety trials and the FDA's classification of the peptide as a Category 2 substance due to immunogenicity concerns suggest a cautious outlook for clinical application. Currently, there are no FDA-approved indications for BPC-157.

    7. Sources

    • TruthTides Peptide Database: BPC-157 Compound Record (2026).
    • FDA Regulatory Status Report: Category 2 Bulk Substances (Sept 2023).
    • ClinicalTrials.gov: NCT074375, NCT02637284.
    • FDA Warning Letters: Tailor Made Compounding (2020); Predator Nutrition (Oct 2020).

    For practitioners interested in evaluating emerging research or discussing these findings with patients, it is important to utilize regulated clinical channels. You can explore further information or find a doctor who specializes in metabolic research to discuss the implications of current peptide literature. If you are looking for localized expertise, searching for peptide therapy near me can connect you with clinics currently monitoring these clinical developments.

    Referenced Peptides

    bpc 157

    This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.